| PMV Pharmaceuticals | Phase 2 | $71.5M | Oncology, Precision Medicine |
| Lusaris Therapeutics | phase-1 | — | Psychiatry, Neuroscience |
| Advanced Cellular Dynamics | Phase 1/2 | — | Oncology, Autoimmune Diseases |
| Nature's Toolbox | — | — | Oncology, Infectious Disease |
| Indapta Therapeutics | Phase 1 | — | Oncology, Autoimmune Diseases |
| Verdiva Bio | Phase 2 | — | Obesity, Cardiometabolic Disorders |
| Navigator Medicines | Phase 2 | — | Inflammatory Disorders, Autoimmune Diseases |
| Be Biopharma | Phase 1 | — | Rare Diseases, Hematology |
| Dignify Therapeutics | Pre-clinical | — | Urology, Gastroenterology |
| Vivace Therapeutics | Phase 2 | — | Oncology |
| Capacity Bio | Pre-clinical | — | Mitochondrial Dysfunction, Aging |
| Jnana Therapeutics | phase-1 | — | Immunology, Metabolic |
| ProfoundBio | phase-2 | — | Oncology |
| Carmot Therapeutics | phase-2 | — | Metabolic Disease, Oncology |
| Marea Therapeutics | phase-2 | — | Metabolic, Cardiovascular |
| GeneCure | phase-1 | — | Rare Disease, Genetics & Genomics |
| ViralGuard | phase-1 | — | Infectious Disease |
| ImmunoLogic | phase-2 | — | Infectious Disease, Immunology |
| OncoImmuno | phase-1 | — | Oncology, Immunology |